Table 4.
Pre-MARS values for bleeding and non-bleeding sessions based on rate of hemoglobin decrease during MARS
| Variable | Bleeding sessions (n=14) | Non-bleeding sessions (n=13) | P-value |
|---|---|---|---|
| Support modality | |||
| CRRT | 11 (78.6) | 9 (69.2) | 0.685 |
| Mechanical ventilation | 4 (28.6) | 1 (7.7) | 0.375 |
| Vasopressor | 4 (28.6) | 1 (7.7) | 0.375 |
| Complete blood count | |||
| Hemoglobin (g/dl) | 9.4±2.2 | 10.1±1.5 | 0.054 |
| Platelet (×103/mm3) | 87.2±41.3 | 89.7±30.4 | 0.616 |
| Laboratory parameter | |||
| AST (IU/L) | 347±499 | 857±1506 | 0.519 |
| ALT (IU/L) | 350±599 | 986±1213 | 0.239 |
| Total bilirubin (mg/dl) | 34.1±11.1 | 25.1±13.3 | 0.066 |
| Direct bilirubin (mg/dl) | 19.6±7.7 | 16.7±9.1 | 0.379 |
| Albumin (g/dl) | 3.3±0.4 | 3.4±0.4 | 0.820 |
| Creatinine (mg/dl) | 1.8±0.9 | 1.5±0.8 | 0.759 |
| Ammonia (µmol/L) | 95.5±72.0 | 96.0±40.9 | 0.350 |
| LD (IU/L) | 1,265±1,088 | 1,534±1,690 | 0.943 |
| Coagulation profile | |||
| PT-INR | 2.7±1.1 | 2.0±0.3 | 0.038 |
| aPTT (sec) | 46.4±5.8 | 45.5±13.5 | 0.141 |
| Fibrinogen (mg/dl) | 163±84 | 159±43 | 0.859 |
| FDP (mg/ml) | 106.9±106.8 | 98.4±98.7 | 0.810 |
| Anti-thrombin Ⅲ (%) | 26.6±12.4 | 26.4±7.7 | 0.955 |
| D-dimer (mg/L FEU) | 32.1±45.6 | 32.3±39.5 | 0.689 |
| Coagulation factor | |||
| Factor Ⅱ (%) | 33.5±8.8 | 39.6±10.8 | 0.270 |
| Factor Ⅴ (%) | 24.8±16.8 | 45.6±21.2 | 0.023 |
| Factor Ⅶ (%) | 19.3±9.2 | 25.0±8.3 | 0.222 |
| Factor Ⅹ (%) | 41.5±15.2 | 52.3±18.9 | 0.212 |
Values are presented as number (%) or mean±standard deviation.
MARS: molecular adsorbent recirculating system; CRRT: continuous renal replacement therapy; AST: aspartate transaminase; ALT: alanine aminotransferase; LD: lactate dehydrogenase; PT-INR: international normalized ratio of prothrombin time; aPTT: activated partial thromboplastin time; FDP: fibrinogen degradation product; FEU: fibrinogen equivalent unit.